Corteva (NYSE:CTVA) Rating Lowered to “Neutral” at JPMorgan Chase & Co.

Corteva (NYSE:CTVA) was downgraded by equities research analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, Marketbeat.com reports. They presently have a $77.00 price objective on the stock, up from their previous price objective of $75.00. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 6.02% from the stock’s current price.

A number of other equities analysts have also issued reports on the company. Citigroup increased their price objective on Corteva from $70.00 to $74.00 and gave the stock a “neutral” rating in a report on Wednesday, January 21st. Oppenheimer boosted their target price on Corteva from $76.00 to $78.00 and gave the stock an “outperform” rating in a report on Tuesday, January 27th. Weiss Ratings reissued a “hold (c-)” rating on shares of Corteva in a research note on Monday, December 29th. Deutsche Bank Aktiengesellschaft lowered their target price on Corteva from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Finally, UBS Group cut their price target on shares of Corteva from $85.00 to $81.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Corteva has a consensus rating of “Moderate Buy” and an average price target of $82.37.

Corteva Price Performance

Shares of Corteva stock opened at $72.63 on Thursday. The business’s fifty day moving average price is $68.82 and its 200 day moving average price is $68.42. Corteva has a twelve month low of $53.40 and a twelve month high of $77.41. The company has a current ratio of 1.43, a quick ratio of 1.07 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $49.08 billion, a P/E ratio of 45.97, a PEG ratio of 1.84 and a beta of 0.75.

Corteva (NYSE:CTVA) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, hitting analysts’ consensus estimates of $0.22. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period last year, the business posted $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, research analysts anticipate that Corteva will post 2.96 earnings per share for the current year.

Institutional Investors Weigh In On Corteva

Hedge funds have recently modified their holdings of the business. Evoke Wealth LLC lifted its holdings in shares of Corteva by 6.1% during the 4th quarter. Evoke Wealth LLC now owns 6,473 shares of the company’s stock worth $434,000 after acquiring an additional 371 shares during the period. Axxcess Wealth Management LLC grew its position in Corteva by 68.5% in the fourth quarter. Axxcess Wealth Management LLC now owns 51,840 shares of the company’s stock valued at $3,475,000 after acquiring an additional 21,075 shares during the period. Global Retirement Partners LLC boosted its stake in shares of Corteva by 25.4% in the 4th quarter. Global Retirement Partners LLC now owns 6,997 shares of the company’s stock valued at $469,000 after purchasing an additional 1,418 shares in the last quarter. Twin Capital Management Inc. grew its holdings in shares of Corteva by 178.9% in the 4th quarter. Twin Capital Management Inc. now owns 25,394 shares of the company’s stock worth $1,702,000 after purchasing an additional 16,288 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in Corteva during the 4th quarter valued at about $2,350,000. 81.54% of the stock is owned by institutional investors.

Key Headlines Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise
• Positive Sentiment: Brokerage consensus remains constructive (consensus “Moderate Buy”), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy
• Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role
• Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views
• Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution
• Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall
• Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade
• Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.